ultiva remifentanil (as hydrochloride) 5mg powder for injection vial
aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty 5 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.
ultiva remifentanil (as hydrochloride) 2mg powder for injection vial
aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty 2 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.
ultiva remifentanil (as hydrochloride) 1mg powder for injection vial
aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty 1 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.
ultiva 5 mg
padagis israel agencies ltd, israel - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 5 mg/vial - remifentanil - remifentanil - ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
oat (cultivated) (avena sativa) pollen 50,000bu/ml solution for skin prick test
cultivated) (avena sativa) pollen 50,000bu/ml solution for skin prick test (allergopharma - oat (cultivated) (avena sativa) pollen allergen extract - solution for skin-prick test
ultiva 1 mg
perrigo israel agencies ltd - remifentanil as hydrochloride - powder for reconstitution for solution for injection - remifentanil as hydrochloride 1 mg/vial - remifentanil - remifentanil - ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
ultiva 2 mg
perrigo israel agencies ltd - remifentanil as hydrochloride - powder for reconstitution for solution for injection - remifentanil as hydrochloride 2 mg/vial - remifentanil - remifentanil - ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
guna-spasm- atropine sulfate - berberis vulgaris root bark - chelidonium majus - cobalt - cultivated mushroom - gelsemium semper
guna spa - cultivated mushroom (unii: 54c8e6w6jy) (cultivated mushroom - unii:54c8e6w6jy), anti-interleukin-1.alpha. immunoglobulin g rabbit (unii: ml4qrz1hcl) (anti-interleukin-1.alpha. immunoglobulin g rabbit - unii:ml4qrz1hcl), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), metenkefalin (unii: 9jez9od3as) (metenkefalin - unii:9jez9od3as), chelidonium majus (unii: 7e889u5rnn) (chelidonium majus - - cultivated mushroom 4 [hp_x] in 30 ml - agaricus campestris 4x antispastic anti interleukin 1 alpha 4c anti-inflammatory atropinum sulfuricum 6x pain relief berberis vulgaris 3x detoxification beta-endorphin 4c pain relief chelidonium majus 4x detoxification cobaltum metallicum 4x antispastic colocynthis 4x back sore gelsemium 6x analgesic interleukin 10 4c anti-inflammatory magnesium metallicum 4x antispastic melatonin 4c antispastic sympathetic nerve 200x pain relief vagal nerve 6x pain relief temporary relief of: - muscle spasms - colic gas pain take 15 minutes before meals
ultiva- remifentanil hydrochloride injection, powder, lyophilized, for solution
mylan institutional llc - remifentanil hydrochloride (unii: 5v444h5wic) (remifentanil - unii:p10582jyyk) - remifentanil 1 mg in 1 ml - ultiva is indicated for intravenous (iv) administration: ultiva is contraindicated: prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. available data with remifentanil hydrochloride in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in animal reproduction studies, reduced fetal rat body weight and pup weights were reported at 2.2 times a human intravenous infusion of an induction dose of 1 mcg/kg with a maintenance dose of 2 mcg/kg/min for a surgical procedure lasting 3 hours. there were no malformations noted when remifentanil was administered via bolus injection to pregnant rats or rabbits during organogenesis at doses approximately 5 times and approximately equal, respectively, to a human intravenous infusion of an induction dose of 1 mcg/kg with a maintenance dose of 2 mcg/kg/min for a surgical procedure lasting 3 hours [see data ]. the estimated background risk of major birth defects and miscarriage
ultiva- remifentanil hydrochloride injection, powder, lyophilized, for solution
mylan institutional llc - remifentanil hydrochloride (unii: 5v444h5wic) (remifentanil - unii:p10582jyyk) - ultiva is indicated for intravenous (iv) administration: ultiva is contraindicated: prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. available data with remifentanil hydrochloride in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in animal reproduction studies, reduced fetal rat body weight and pup weights were reported at 2.2 times a human intravenous infusion of an induction dose of 1 mcg/kg with a maintenance dose of 2 mcg/kg/min for a surgical procedure lasting 3 hours. there were no malformations noted when remifentanil was administered via bolus injection to pregnant rats or rabbits during organogenesis at doses approximately 5 times and approximately equal, respectively, to a human intravenous infusion of an induction dose of 1 mcg/kg with a maintenance dose of 2 mcg/kg/min for a surgical procedure lasting 3 hours [see data ]. the estimated background risk of major birth defects and miscarriage